

# California Department of Public Health



Karen L. Smith, MD, MPH  
Director and State Health Officer

Edmund G. Brown Jr Governor

## Office of AIDS (OA)

## Management Memorandum

### AIDS Drug Assistance Program (ADAP)

Memorandum Number: 2017-01

DATE: JANUARY 3, 2017

TO: LOCAL ADAP COORDINATORS AND ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF SOFOSBUVIR/VELATASVIR (EPCLUSA™) TO THE ADAP FORMULARY

**Effective December 28, 2016**, sofosbuvir 400 mg/velatasvir 100 mg (Epclusa), has been added to the ADAP formulary. This once-daily combination drug was approved by the federal Food and Drug Administration (FDA) on June 28, 2016 for the treatment of individuals with genotype 1-6 chronic hepatitis C virus (HCV) infection. This HCV drug can be administer with or without ribavirin.

With the addition of this Epclusa™, the ADAP formulary consists of over 200 drugs, including those necessary to treat HIV in accordance with the federal treatment guidelines for HIV/AIDS and associated opportunistic infections.

If you have any questions regarding the addition of this drug to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Sincerely,

A handwritten signature in blue ink that reads "Majel Arnold, MSN".

Majel Arnold, Acting Chief

ADAP Branch

Office of AIDS

Office of AIDS, MS 7700, P.O. Box 997426, Sacramento, CA 95899-7426

Telephone (844) 421-7050 / Fax (916) 440-5490

Internet Address: <https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAmain.aspx>

